F2R and Arterial thrombosis: As a result, robust and specific PAR4 antagonists, such as those currently being pursued [51], are required to further examine the possibility that PAR1 and PAR4 on human platelets perform separate functions, and to determine whether selective inhibition of these two thrombin receptors will provide distinct utility in the prevention of arterial thrombosis.